Use access key #2 to skip to page content.
$17.01 -0.30 (-1.73%)
7/18/2008 4:00 PM

Regeneron Pharmaceuticals, Inc. (REGN)

CAPS Rating:
*

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating REGN

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

69 Outperforms
38 Underperforms
 

All-Stars

23 Outperforms
26 Underperforms
 

Wall Street

6 Outperforms
1 Underperforms
 

Players bullish on REGN are also bullish on:

Players bearish on REGN are also bearish on:

Ticker Tags

Biotechnology (293), Small Cap (1922)
Suggest a tag

Regeneron Pharmaceuticals, Inc. At A Glance

Current Price: $17.01
Last Trade Time: 7/18/2008 4:00 PM
Open: $17.26
Previous Close: $17.31
Daily Range: $16.65 - $17.37
52-Week Range: $13.29 - $25.00
Volume: 559,977
Market Cap: $1.33B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

REGN VS S&P 500 (SPY)

REGN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for REGN

More Headlines...

Top Bull Pitch

Recs

2

Regeneron Pharmaceuticals, Inc. (REGN)

Avatar daviddai (< 20) Submitted: 3/08/07 12:26 PM

The stock has strong therapeutic candidates (interleukin-1 trap and VEGF trap) which, I believe, are likely be approved by FDA in the coming years. This will give them the profit margin that they so desperate need in order to expand their R&D for more drug discovery. They also have very strong R&D...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

Regeneron Pharmaceuticals, Inc. (REGN)

Avatar GunnarVagotis (96.02) Submitted: 11/29/07 10:17 AM

Regeneron? That's all I need to know. If they had any sack whatsoever the company would be called Regeneronotronix.

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 14 :   1 2 3 Next »

Recs

0

 (REGN)

Avatar giffman62 (< 20) Submitted: 6/06/08 2:24 AM : Outperform Start Price: $15.22 REGN Score: 21.99

Trading too low now, correction is on the horizon.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar jsIRA (83.00) Submitted: 6/03/08 5:35 PM : Outperform Start Price: $18.64 REGN Score: -0.16

Good bio tech company. Will see year high soon

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (REGN)

Avatar digitaldad1 (< 20) Submitted: 1/22/08 5:11 PM : Outperform Start Price: $23.88 REGN Score: -27.95

Big Pharma now owns 19% at a recent cost of $26.00.
Regeneron shares in the eventual profits while having all the costs covered by payments from this company.
A anti cancer drug promise for tumors is resting on Regeneron and the recent headline says it all:
Regeneron Closes $312 Million Common Stock Sale in Connection with Sanofi-Aventis Collaboration

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (REGN)

Avatar kurthauer1998 (95.34) Submitted: 1/21/08 4:41 PM : Underperform Start Price: $24.00 REGN Score: 28.21

The company's clinical development programs include Interleukin-1 (IL-1) Trap for various inflammatory indications, VEGF Trap for oncology, and VEGF Trap-Eye formulation for eye diseases. The IL-1 Trap is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors. The VEGF Trap is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor. The VEGF Trap-Eye is a form of VEGF Trap for direct injection into the eye, which is tested in a Phase II clinical trial in patients with the neovascular form of age-related macular degeneration and in patients with diabetic macular edema. The company has a collaboration agreement with sanofi-aventis Group for the development of the VEGF Trap in cancer indications and to develop fully-human therapeutic antibodies, as well as with Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

20yrs lot's of gibberish key statistics extremly negative.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (REGN)

Avatar GunnarVagotis (96.02) Submitted: 11/29/07 10:17 AM : Underperform Start Price: $22.86 REGN Score: 11.70

Regeneron? That's all I need to know. If they had any sack whatsoever the company would be called Regeneronotronix.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 14 :   1 2 3 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackZacks 90.46 01/14/08 01/14/08 Outperform 3M $24.54-30.68%-10.78%-19.90 Toggle the visibility of 60-Second Pitch and replies
TrackCarisandCo 79.10 12/03/07 12/03/07 Outperform NS $22.30-23.72%-14.94%-8.78
TrackCanaccord 86.17 11/02/07 11/02/07 Outperform NS $21.19-19.73%-16.05%-3.68
TrackIcahn 91.10 09/30/07 09/30/07 Outperform NS $17.80-4.44%-17.39%+12.95 Toggle the visibility of 60-Second Pitch and replies
TrackNeedham < 20 11/08/06 11/08/06 Outperform NS $23.95-28.98%-8.50%-20.48
TrackRBCCapMkts 90.79 10/19/06 10/19/06 Outperform NS $19.50-12.77%-7.55%-5.22
TrackLehmanBros 87.77 10/19/06 10/19/06 Outperform NS $19.50-12.77%-7.55%-5.22
TrackJimCramer 82.55 08/16/06 08/16/06 Underperform 3W $14.86+14.47%-3.29%-17.76

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners